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Identification and validation of 
candidate epigenetic biomarkers in 
lung adenocarcinoma
Iben Daugaard1, Diana Dominguez1, Tina E. Kjeldsen1, Lasse S. Kristensen1, Henrik Hager2, 
Tomasz K. Wojdacz1,3,* & Lise Lotte Hansen1,*
Lung cancer is the number one cause of cancer-related deaths worldwide. DNA methylation is an 
epigenetic mechanism that regulates gene expression, and disease-specific methylation changes can be 
targeted as biomarkers. We have compared the genome-wide methylation pattern in tumor and tumor-
adjacent normal lung tissue from four lung adenocarcinoma (LAC) patients using DNA methylation 
microarrays and identified 74 differentially methylated regions (DMRs). Eighteen DMRs were selected 
for validation in a cohort comprising primary tumors from 52 LAC patients and tumor-adjacent normal 
lung tissue from 32 patients by methylation-sensitive high resolution melting (MS-HRM) analysis. 
Significant increases in methylation were confirmed for 15 DMRs associated with the genes and 
genomic regions: OSR1, SIM1, GHSR, OTX2, LOC648987, HIST1H3E, HIST1H3G/HIST1H2BI, HIST1H2AJ/
HIST1H2BM, HOXD10, HOXD3, HOXB3/HOXB4, HOXA3, HOXA5, Chr1(q21.1).A, and Chr6(p22.1). In 
particular the OSR1, SIM1 and HOXB3/HOXB4 regions demonstrated high potential as biomarkers in 
LAC. For OSR1, hypermethylation was detected in 47/48 LAC cases compared to 1/31 tumor-adjacent 
normal lung samples. Similarly, 45/49 and 36/48 LAC cases compared to 3/31 and 0/31 tumor-adjacent 
normal lung samples showed hypermethylation of the SIM1 and HOXB3/HOXB4 regions, respectively. In 
conclusion, this study has identified and validated 15 DMRs that can be targeted as biomarkers in LAC.
Lung cancer is the most common type of cancer and each year, the disease is responsible for approximately 
1.5 million deaths worldwide1,2. There are two major types of lung cancer; small cell lung cancer (SCLC) and 
non-small cell lung cancer (NSCLC) accounting for 10% and 85%, of all newly diagnosed lung cancers, respec-
tively. Lung adenocarcinoma (LAC) is the most common subtype of NSCLC, which account for approximately 
40% of all lung cancers3. The overall 5-year survival rate for lung cancer is 15%, but the prognosis is highly 
dependent on the stage, at which the disease is diagnosed4,5. If the disease is localized at the time of diagnosis, the 
5-year survival rate is approximately 50%, compared to approximately 25% for cases with regional disease, and 
less than 5% for patients that already suffer from metastatic disease3. Most early stage lung cancers are asympto-
matic and consequently, only 15% of lung cancers are diagnosed at a local stage and more than 50% are diagnosed 
at an advanced stage3. Thus, new efficient diagnostic tools for early and accurate disease detection are needed in 
order to improve the poor prognosis of lung cancer.
Methylation of the carbon-5 position of cytosine residues within CpG dinucleotides is a well-established 
epigenetic mechanism involved in the regulation of gene expression6. Most CpG dinucleotides cluster in CpG 
rich regions in the genome, known as CpG islands (CGI), and these regions are often located within gene reg-
ulatory elements7. In fact, the promoter region of more than half of all protein encoding genes contain a CGI 
and the methylation status of this sequence is instrumental in regulating the transcriptional activity of the 
gene8. Consequently, disruption of the cell’s normal methylation pattern can have severe consequences and 
contribute to neoplastic transformation7–9. Genome-wide studies have shown that aberrant DNA methyla-
tion is a common feature in human cancer and hundreds of tumor suppressor genes have been shown to be 
subject to DNA-methylation mediated silencing6,10–12. Gene expression changes as a consequence of aberrant 
methylation have also been reported for multiple genes in lung cancer, especially hypermethylation-mediated 
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silencing of tumor suppressor genes such as RASSF1A, APC, RARβ, DAPK and MGMT, and to a lesser extent, 
hypomethylation-mediated overexpression of proto-oncogenes such as ELMO313–17.
The utility of DNA methylation biomarkers has already been established in all aspects of clinical cancer man-
agement, including risk assessment, early disease detection, prognostication and treatment personalization18–22. 
However, the development of biomarkers for clinical implementation is a challenging process that includes 
biomarker candidate discovery and evaluation of biomarker specificity and sensitivity in large-scale validation 
studies.
Here, we have performed a genome-wide methylation screening and identified novel methylation biomarker 
candidates that can potentially be used in clinical lung cancer management. We have identified cancer-specific 
methylation changes and performed a preliminary validation and evaluated the sensitivity and specificity of the 
most promising candidate biomarkers.
Results
Identification of differentially methylated regions (DMRs) in LAC. In order to identify novel 
genomic regions with disease-specific changes in methylation, we performed a genome-wide methylation screen-
ing of tumor and tumor-adjacent normal lung tissue from four LAC patients using the NimbleGen Human DNA 
Methylation 3 × 720 K CpG Island Plus RefSeq Promoter Array, which interrogates 15,980 CpG islands and 
20,404 reference gene promoter regions23. After data processing, a total of 346 probes (oligonucleotides of 60 bp 
spotted on the array) demonstrated a significant change in methylation levels between the tumor and tumor-ad-
jacent normal lung tissue with 288 (83.2%) and 58 (16.7%) reporting hyper- and hypomethylation in the tumor 
tissue, respectively. The mapping of the probes to genomic regions revealed no enrichment bias in any specific 
parts of the genome. Out of the 346 probes, 131 (37.9%) were located within known CGIs, 164 (47.4%) at CGI 
shores, 6 (1.7%) in CGI shelves and 45 (13.0%) were not associated with any known CGIs. When mapping to 
genes, 176 (50.9%) probes were intragenic, 128 (37.0%) were located < 5 kb upstream of known genes, 3 (0.9%) 
were located < 5 kb downstream of known genes, and 39 (11.2%) were not associated with any known gene. The 
346 probes were sorted by differential methylation score, which indicates the magnitude of the detected change in 
methylation (See Methods section: Microarray analyses). A complete list including genomic location and position 
relative to known genes and CGIs is shown in Supplementary Table S1. To locate the most informative differen-
tially methylated regions (DMRs) in LAC, we grouped the probes with a maximum inter-probe distance of 5 kb. 
Using this approach, we identified a total of 74 DMRs of which 63 (85.1%) showed hypermethylation and 11 
(14.9%) hypomethylation in LAC. Each DMR was on average targeted by 4.1 probes (Range: 2–13 probes) and 
spanned 547.3 bp (Range: 126–4245 bp). Of the 74 DMRs, 65 (87.8%) and 66 (89.2%) were located in association 
with known genes and CGIs, respectively. Several of the identified DMRs, including OTX2, OSR1 and GHSR, have 
previously been reported differentially methylated in LAC24,25. A complete list of the 74 identified DMRs, includ-
ing genomic location, differential methylation scores and location relative to known genes and CGIs, is shown 
in Supplementary Table S2. The DMRs were sorted according to the probe with highest differential methylation 
score in each region and the asterisks denote the DMRs that were selected for further validation.
Validation of candidate DNA methylation biomarkers. To evaluate our findings potential for clinical 
application, we selected 18 DMRs based upon highest differential methylation score and the number of probes 
targeting the region to undergo validation in a LAC validation cohort, comprising 52 primary lung tumors, 24 
paired distant metastases (20 brain and 4 adrenal gland) and 32 tumor-adjacent normal lung samples. The histo-
logical and clinical characteristics of the patients are shown in Supplementary Table S3, and the selected DMRs 
are indicated with an asterisk in Supplementary Table S2. The array data showed that 16 of the 18 selected DMRs 
were hypermethylated and two regions, FRG1BP and CTAGE15, were hypomethylated in primary tumors com-
pared to tumor-adjacent normal lung tissue. We then assessed the methylation status of each of the 18 candidate 
regions in our patient samples using Methylation-Sensitive High Resolution Melting (MS-HRM) analysis. The 
genomic location of the MS-HRM assays is shown in Table 1 and the technical specifications for each assay in 
Supplementary Methods. The results of the MS-HRM-based methylation assessment are summarized in Table 2 
and displayed as stacked bar percentage plots in Fig. 1. Using this approach, we were able to confirm a significant 
increase in methylated templates in the tumor samples for 15 of the 18 selected DMRs corresponding to the 
hypermethylation indicated by the array analysis. Normalized melting curves for representative tumor and nor-
mal lung samples are shown in Fig. 2 for the HOXD3, OSR1 and HIST1H3E MS-HRM assays, where the gain in 
methylation is seen as a relative shift in the melting curves towards the 100% methylated standard. We were una-
ble to confirm the array results for three DMRs, including one hypermethylated region, LY75-CD302, and both 
hypomethylated regions, FR1GB and CTAGE15, as shown in Fig. 1j,m,n. For 12 of the 15 DMRs with concordant 
MS-HRM and array results, the difference in methylation frequency between tumor and normal lung tissue was 
very pronounced as indicated by the p-values (p < 0.0001) in Fig. 1. As an example, an elevated methylation level 
was detected in 75% of the tumor samples and 0% of the normal lung samples for the HOXB3/HOXB4 MS-HRM 
assay, as shown in Fig. 1c, and in 87.9% of the tumor samples and only 3.2% of the normal lung samples for the 
OSR1 MS-HRM assay shown in Fig. 1i. A high methylation frequency was also observed in the brain and adrenal 
gland metastases for all 15 confirmed DMRs. For the majority of the DMRs, the detected increase in methylation 
was even more prominent in the metastases compared to primary tumors, but due to the considerable difference 
in average tumor content between the primary tumors and metastases samples listed in Supplementary Table S3, 
these groups are not directly comparable. In conclusion, we have identified and validated 15 DMRs that can be 
targeted as novel biomarkers in LAC.
The candidate DNA methylation biomarkers are not predictive of metastases formation in 
LAC. The presence of metastatic disease greatly reduces the overall survival of LAC patients. To determine if 
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hypermethylation of the 15 identified candidate biomarkers are predictive of metastases formation in LAC, we 
compared the methylation status of the 15 DMRs between metastases-free patients with a minimum of 5 years 
recurrence-free survival, and patients that suffered from distant metastatic disease at the time of diagnosis. The 
results are shown in Supplementary Table S4. We did not detect a significant difference in methylation frequency 
between the metastasizing and non-metastasizing tumors for any of the 15 DMRs. However, three of the DMRs, 
HOXB3/HOXB4, LOC648987 and HOXA5, showed a trend towards an increase in methylation in the metastasiz-
ing tumors as illustrated in Fig. 3a–c. At the HOXB3/HOXB4 region, we detected increased methylation in 15 of 
24 (62.5%) non-metastasizing tumors compared to in 21 of 24 (87.5%) metastasizing tumors. Similarly, increased 
methylation in 3 out of 21 (14.3%) non-metastasizing tumors and in 8 out of 24 (33.3%) metastasizing tumors 
were detected for the LOC648987 region, as well as in 19 out of 26 (73.1%) non-metastasizing tumors compared 
to 23 out of 26 (88.4%) metastasizing tumors for the HOXA5 region. For all three DMRs, a similar increase in 
methylation was detected in the paired brain and adrenal gland metastases, as shown in Table 2.
Evaluation of the clinical potential of the candidate DNA methylation biomarkers. Sensitivity 
and specificity are the most important parameters when describing the potential diagnostic applicability of a 
biomarker. In order to calculate these values, we determined an unambiguous consensus for when a sample was 
considered methylation positive or negative for each assay. MS-HRM is a semi-quantitative method capable of 
determining the relative amount of methylated alleles in a sample, and we therefore determined a specific cutoff 
value for each of the assays based on the relative amount of methylated alleles that is detected. For each potential 
cutoff value, we calculated the corresponding sensitivity and specificity, and the cutoff was then set to achieve 
maximal sensitivity without compromising a specificity limit of 0.8. The determined cutoff value, sensitivity and 
specificity for each candidate biomarker are shown in Table 3. For 9/15 assays, the cutoff was set at 1% methyla-
tion and all samples containing more than 1% methylated templates were therefore considered positive. Similarly, 
the cutoff was set at > 10% methylation for the HOXD3, Chr1(q21.1).A and GHSR assays and at > 50% methyla-
tion for the HOXA3, HOXA5 and HIST1H3E assays. Using this approach, we achieved a specificity of ≥ 0.90 for 
all assays, except HOXD10, and 9/15 assays reached a specificity of 1.00, which translates into a false positive rate 
of 0%. The sensitivity ranged from 0.12 to 0.98 with 8/15 assays demonstrating a sensitivity of ≥ 0.75.
While it is possible to successfully employ cutoff values when using MS-HRM analysis, it is still preferential 
to use biomarkers that do not show any methylation in the corresponding normal tissue, as this allows for more 
accurate and stringent analyses. To identify the most promising candidate biomarkers, we therefore applied a 
lower sensitivity limit of 0.75 and a lower specificity limit of 0.90 to the assays with a cutoff of > 1% methylation. 
Three candidate biomarkers fulfilled these criteria, OSR1, SIM1 and HOXB3/HOXB4, which are indicated in bold 
print in Table 3. The OSR1 assay demonstrated a sensitivity of 0.98 and a specificity of 0.97 and correctly identified 
97% of all tested samples. The SIM1 assay correctly identified 91% of the samples and showed a sensitivity of 0.92 
and a specificity of 0.90 and similarly, the HOXB3/HOXB4 assay provided a sensitivity of 0.75 and a specificity 
of 1.00 and therefore correctly identified 85% of the tested samples. The OSR1, SIM1, HOXB3/HOXB4 DMRs 
therefore show high clinical potential as biomarkers in LAC.
ID
DMR MS-HRM assay location relative to known genes and CpG Islands (CGI)
No. Diff. Methylation Score
Diff. Methylation 
Hypo (−)/Hyper (+) Upstream Intragenic Downstream CGI Location (Hg38)
OTX2 1 9.130 + OTX2 Island chr14: 56809871–56809962
HOXD3 2 8.830 + HOXD3 Shore chr2: 176162676–176162747
HOXB3/HOXB4 3 7.625 + HOXB3 HOXB4 Shore chr17: 48577876–48577988
HOXD10 4 7.318 + HOXD10 Island chr2:176117574–176117651
Chr1(q21.1).A 5 6.765 + Island chr1:147080162–147080262
HIST1H3G/HIST1H2BI 6 6.749 + HIST1H3G, HIST1H2BI Island chr6:26272252–26272379
GHSR 7 6.585 + GHSR Island chr3:172448360–172448447
SIM1 8 6.191 + SIM1 Island chr6:100465031–100465125
OSR1 9 6.117 + OSR1 Island chr2:19357150–19357251
FRG1BP 10 5.838 − FRG1BP Island chr20: 30377475–30377573
Chr6(p22.1) 13 5.653 + Island chr6:28207550–28207669
HOXA3 15 5.435 + HOXA3 HOXA4 Island chr7: 27124232–27124343
LY75-CD302 17 5.223 + LY75-CD302, CD302 LY75 Island chr2: 159797756–159797835
CTAGE15 18 5.217 − CTAGE15 chr7: 143571685–143571797
LOC648987 19 4.790 + ANXA2R LOC648987 Island chr5: 43040396–43040521
HIST1H2AJ/HIST1H2BM 21 4.635 + HIST1H2BM HIST1H2AJ Island chr6:27814577–27814732
HOXA5 22 4.522 + HOXA5 HOXA6 Island chr7: 27143474–27143563
HIST1H3E 61 2.961 + HIST1H3E Island chr6:26225275–26225421
Table 1.  DMRs selected for validation by MS-HRM analysis.
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Discussion
Lung cancer has the highest mortality rates among cancers, but the prognosis for the individual patient varies 
considerably depending on the stage at which the disease is diagnosed3. Efficient diagnostic tools that allow 
early and accurate disease detection are therefore of critical importance in clinical lung cancer management. 
Compelling evidence supporting the utility of methylation biomarkers in various aspects of cancer management, 
such as risk assessment, disease detection and personalization of treatment, has accumulated during the last 
decades18. In this study, we aimed to identify and validate novel DMRs in LAC that can be targeted as biomark-
ers. Using a microarray-based genome-wide methylation screening approach, we identified 74 genomic regions 
that demonstrated differential methylation in tumor and tumor-adjacent normal lung tissue. Eighteen DMRs 
were selected for validation by MS-HRM analysis and we were able to confirm differential methylation in 15/18 
DMRs. This yields a true positive rate of 83.3%, which indicates that the obtained microarray data is of high qual-
ity, but also emphasizes the importance of a thorough validation process when performing a microarray-based 
genome-wide methylation screening study. The validity of the data is furthermore supported by the fact that we 
were able to confirm differential methylation for the HIST1H3E region, which is number 61 out of the 74 identi-
fied DMRs when sorted by highest differential methylation score (See Supplementary Table S2). The HIST1H3E 
region was only targeted by 3 probes and only showed a differential methylation score of 2.961 and we still con-
firmed a significant increase in methylation (p < 0.0001) in the tumor samples as illustrated in Figs 1r and 2e,f. 
Moreover, Rauch et al. recently published a similar methylation screening study using 8 LAC patient samples and 
there are several overlaps in the identified DMRs, which serves to confirm the validity of both studies25.
Most of the DMRs identified in our study showed hypermethylation in LAC. In fact, 85.1% of all of the 74 
identified DMRs and all 15 confirmed DMRs were hypermethylated. This overrepresentation of hypermethylated 
DMRs can be explained by the fact that the microarray used in our study is designed to specifically target CpG 
islands and reference gene promoter regions, which are known to frequently undergo de novo DNA methylation 
during tumorigenesis6,10.
In order for a biomarker to be clinically relevant, it needs to be capable of distinguishing cancerous from 
healthy tissue with high sensitivity and specificity, as well as deliver unambiguous results. MS-HRM analysis 
allows implementation of assay-specific cutoff values, which can be useful when investigating methylation 
changes in regions with frequent low-level methylation in the surrounding non-cancerous tissue. However, the 
use of assay-specific cutoff values is challenging for clinical purposes, as a tumor-related increase in methylation 
can be easily masked by the normal methylation level in contaminating normal cells, which are inevitably present 
in surgical resections and biopsies. The tumor cell content in clinical specimens vary extensively between samples 
and the biomarker assessment assays therefore require a high dynamic range in order to successfully test samples 
with both high and low tumor content and this is difficult to achieve when introducing higher cutoff values. 
While this can be overcome through macro- or microdissection of each specimen prior to biomarker assessment, 
ID
Normal Lung Lung Tumor Metastases
PMethylation Level Methylation Level Methylation Level
0–1%  
n (%)
1–10%  
n (%)
10–50% 
n (%)
50–100% 
n (%) N (%)
0–1%  
n (%)
1–10%  
n (%)
10–50% 
n (%)
50–100% 
n (%) N (%)
0–1%  
n (%)
1–10%  
n (%)
10–50% 
n (%)
50–100% 
n (%) N( %)
Tumor 
vs. 
Normal
OTX2 31 (100) 0 (0) 0 (0) 0 (0) 31 (100) 25 (49.0) 26 (51.0) 0 (0) 0 (0) 51 (100) 1 (4.4) 14 (60.8) 7 (30.4) 1 (4.4) 23 (100) < 0.0001
HOXD3 23 (74.2) 7 (22.6) 1 (3.2) 0 (0) 31 (100) 0 (0) 7 (14.0) 34 (68.0) 9 (18.0) 50 (100) 0 (0) 0 (0) 13 (56.5) 10 (43.5) 23 (100) < 0.0001
HOXB3/
HOXB4 31 (100) 0 (0) 0 (0) 0 (0) 31 (100) 12 (25.0) 16 (33.3) 19 (39.6) 1 (2.1) 48 (100) 3 (13.0) 2 (8.7) 13 (56.5) 5 (21.8) 23 (100) < 0.0001
HOXD10 26 (81.3) 6 (18.7) 0 (0) 0 (0) 32 (100) 5 (9.8) 27 (52.9) 18 (35.3) 1 (2.0) 51 (100) 2 (8.3) 10 (41.7) 11 (45.8) 1 (4.2) 24 (100) < 0.0001
Chr1(q21.1).A 15 (50.0) 15 (50.0) 0 (0) 0 (0) 30 (100) 0 (0) 10 (20.8) 32 (66.7) 6 (12.5) 48 (100) 0 (0) 2 (8.7) 12 (52.2) 9 (39.1) 23 (100) < 0.0001
HIST1H3G/
HIST1H2BI 32 (100) 0 (0) 0 (0) 0 (0) 32 (100) 19 (36.5) 27 (51.9) 6 (11.6) 0 (0) 52 (100) 8 (34.8) 6 (26.1) 9 (39.1) 0 (0) 23 (100) < 0.0001
GHSR 11 (35.5) 19 (61.3) 1 (3.2) 0 (0) 31 (100) 2 (4.2) 6 (12.5) 29 (60.4) 11 (22.9) 48 (100) 1 (4.4) 2 (8.7) 11 (47.8) 9 (39.1) 23 (100) < 0.0001
SIM1 28 (90.3) 3 (9.7) 0 (0) 0 (0) 31 (100) 4 (8.2) 22 (44.9) 21 (42.8) 2 (4.1) 49 (100) 1(4.6) 3 (13.6) 14 (63.6) 4 (18.2) 22 (100) < 0.0001
OSR1 30 (96.8) 1 (3.2) 0 (0) 0 (0) 31 (100) 1 (2.1) 12 (25.0) 30 (62.5) 5 (10.4) 48 (100) 3 (13.6) 1 (4.6) 9 (40.9) 9 (40.9) 22 (100) < 0.0001
FRG1BP 0 (0) 0 (0) 32 (100) 0 (0) 32 (100) 0 (0) 4 (7.7) 48 (92.3) 0 (0) 52 (100) 0 (0) 4 (17.4) 17 (73.9) 2 (8.7) 23 (100) 0.159
Chr6(p22.1) 32 (100) 0 (0) 0 (0) 0 (0) 32 (100) 16 (32.6) 13 (26.6) 16 (32.6) 4 (8.2) 49 (100) 5 (21.7) 2 (8.7) 12 (52.2) 4 (17.4) 23 (100) < 0.0001
HOXA3 0 (0) 14 (48.3) 15 (51.7) 0 (0) 29 (100) 0 (0) 3 (6.0) 40 (80.0) 7 (14.0) 50 (100) 0 (0) 6 (26.1) 10 (43.5) 7 (30.4) 23 (100) < 0.0001
LY75-CD302 30 (96.8) 1 (3.2) 0 (0) 0 (0) 31 (100) 47 (97.9) 1 (2.1) 0 (0) 0 (0) 48 (100) 22 (100) 0 (0) 0 (0) 0 (0) 22 (100) > 0.999
CTAGE15 0 (0) 0 (0) 0 (0) 32 (100) 32 (100) 0 (0) 0 (0) 0 (0) 52 (100) 52 (100) 0 (0) 0 (0) 1 (4.4) 22 (95.6) 23 (100) > 0.999
LOC648987 29 (100) 0 (0) 0 (0) 0 (0) 29 (100) 34 (75.5) 7 (15.6) 4 (8.9) 0 (0) 45 (100) 12 (57.1) 4 (19.1) 5 (23.8) 0 (0) 21 (100) 0.005
HIST1H2AJ/
HIST1H2BM 32 (100) 0 (0) 0 (0) 0 (0) 32 (100) 40 (78.4) 11 (21.6) 0 (0) 0 (0) 51 (100) 19 (82.6) 3 (13.0) 1 (4.4) 0 (0) 23 (100) 0.005
HOXA5 0 (0) 11 (35.5) 20 (64.5) 0 (0) 31 (100) 0 (0) 10 (19.2) 36 (69.2) 6 (11.6) 52 (100) 0 (0) 5 (21.7) 8 (34.8) 10 (43.5) 23 (100) 0.035
HIST1H3E 0 (0) 0 (0) 29 (90.6) 3 (9.4) 32 (100) 0 (0) 0 (0) 5 (10.0) 45 (90.0) 50 (100) 0 (0) 0 (0) 1 (4.4) 22 (95.6) 23 (100) < 0.0001
Table 2.  DNA methylation frequencies in tumor-adjacent normal lung, primary lung tumors and distant 
metastases.
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it greatly reduces the time-efficiency and increases the cost of the individual experiment and thus limits the 
clinical potential of a candidate biomarker. It is therefore highly preferential to target regions that do not show 
methylation in normal tissue, as any increase in methylation, regardless of the magnitude, can be attributed to the 
presence of cancerous cells regardless of the tumor content in the clinical specimen.
Figure 1. Differentially methylated regions in LAC. The methylation level of 18 DMRs was investigated in 
52 LAC primary tumors and 32 tumor-adjacent normal lung samples using MS-HRM analysis. The results 
of the methylation assessment are shown as stacked bar percentage plots for each DMR in (a–r). The relative 
proportion of samples in each category with 0–1% methylated templates are shown in white, 1–10% methylated 
templates in white with light grey stripes, 10–50% methylated templates in dark grey and 50–100% methylated 
templates in black. The statistical significance of the detected differences in methylation between groups was 
assessed using a Mann-Whitney test of ranks and two-tailed p-values ≤ 0.05 were considered statistically 
significant.
www.nature.com/scientificreports/
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We have evaluated the sensitivity and specificity for the MS-HRM assays targeting the 15 confirmed DMRs 
and identified the OSR1, SIM1 and HOXB3/HOXB4 regions, which all showed minor to no methylation in 
the surrounding normal tissue, as the most promising biomarkers in LAC. The OSR1 region demonstrated a 
remarkably high sensitivity and specificity, as we detected hypermethylation in 97.9% of the LAC tumors (n = 48) 
and only in 3.2% of the tumor-adjacent normal lung samples (n = 31). The odd-skipped related 1 (OSR1) gene 
encodes a zinc-finger transcription factor that was recently shown to function as a tumor suppressor in gastric 
cancer by activating TP53 transcription26,27. Furthermore, OSR1 was shown to be silenced by promoter hyper-
methylation in 51.8% (n = 164) of gastric cancer patients and was identified as an independent predictor of poor 
survival27. Rauch et al. also reported OSR1 hypermethylation in 100% of the LACs (n = 8) tested in their study, 
which underlines the potential of the region as a diagnostic biomarker in LAC25. The single-minded homolog 1 
(SIM1) region also showed high potential as a biomarker in LAC. SIM1 is frequently methylated in astrocytoma 
and breast cancer, but this study is the first to describe hypermethylation in lung cancer28–30. A substantial subset 
of the 74 identified DMRs, including 5/15 of the validated DMRs, HOXD3, HOXB3/HOXB4, HOXD10, HOXA3 
and HOXA5, were associated with homeobox genes. Hypermethylation of homeobox genes is a common obser-
vation in genome-wide methylation screening studies and have been reported in several cancers, including lung 
cancer25,31–33. While the homeobox genes lack tumor subtype specificity, they may still be useful in combination 
with other diagnostic biomarkers in LAC. The HOXB3/HOXB4 region showed a tendency towards increased 
methylation in metastasizing compared to non-metastasizing tumors. We were unable to identify any DMRs that 
were significantly associated with metastases formation in LAC when studying primary tumors from patients 
with and without distant metastases. We did detect higher methylation levels in the metastases compared to the 
primary tumors for the majority of the DMRs, but these groups were not directly comparable due to the substan-
tial difference in average tumor content. However, these results shows that the hypermethylation observed in the 
primary tumors is maintained during the metastatic process, and suggests that it may play an important role in 
LAC development and progression.
This study was performed using tumor-adjacent normal lung tissue as a control due to the limited availability 
of lung tissue from healthy individuals. We were able to validate differential methylation in 15 DMRs, but it is 
possible that the low-level methylation that is observed in a small subset of the normal samples for several of the 
regions, e.g. HOXD10, HOXD3 and SIM1, is a result of the use of tissue, which have been exposed to the same 
Figure 2. Examples of melting profiles observed for the HOXD3, OSR1 and HIST1H3E regions. The 
methylation level of the 18 DMRs was determined using MS-HRM analysis. Representative normalized melting 
profiles for 10 tumor-adjacent normal lung samples and 10 LAC tumors are shown in black in (a,b) for HOXD3, 
(c,d) for OSR1 and in (e,f) for HIST1H3E. The DNA methylation standards were generated as a serial dilution of 
fully methylated DNA into an unmethylated background. The 100% methylated standard is shown in red, 50% 
methylated standard in light blue, 10% methylated standard in green, 1% methylated standard in dark blue and 
the 0% methylated standard in yellow.
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Figure 3. Methylation levels in metastasizing and non-metastasizing LAC tumors. The methylation levels of 
the 18 DMRs were compared between 26 metastasizing and 26 non-metastasizing LAC primary tumors. Three 
regions demonstrated a tendency towards increased methylation in the metastasizing tumors and a similar 
increase was observed in the 24 paired metastases (20 brain and 4 adrenal gland). The results are shown as 
stacked bar percentage plots in (a) for HOXB3/HOXB4, (b) for LOC648987 and in (c) for HOXA5. The relative 
proportion of samples in each category with 0–1% methylated templates are shown in white, 1–10% methylated 
templates in white with light grey stripes, 10–50% methylated templates in dark grey and 50–100% methylated 
templates in black. The statistical significance of the detected differences in methylation between groups was 
assessed using a Mann-Whitney test of ranks and two-tailed p-values ≤ 0.05 were considered statistically 
significant.
www.nature.com/scientificreports/
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environmental factors as the tumor tissue. It would therefore be highly relevant to investigate if the low-level 
methylation observed in these regions is present in normal lung tissue from healthy individuals as well. If this is 
not the case, then several of the DMRs that were excluded as a result of too low specificity, in particular HOXD3 
and HOXD10, will hold a high clinical potential as well.
The Chr6(p22.1), HIST1H3G/HIST1H2BI and OTX2 regions all demonstrated a specificity of 1.0, but they 
were excluded due to their lower sensitivity of 0.67, 0.63 and 0.51, respectively. It would therefore be interesting 
to investigate the clinical potential of these regions in combination with the three most promising regions, OSR1, 
SIM1 and HOXB3/HOXB4, in a larger LAC cohort.
This study has focused on the discovery of differentially methylated regions between primary tumor and 
tumor-adjacent normal lung tissue and the identified candidate biomarkers can therefore potentially be applied 
diagnostically to separate malignant tumors from benign conditions of the lung where biopsy is indicated. 
Similarly, all primary tumors used in this study were adenocarcinomas and it would therefore be interesting to 
determine if the candidate biomarkers are specific for this subtype of lung cancer, as any candidate biomarkers 
with such specificity may be useful diagnostic tools for tumor sub classification. Furthermore, it would be highly 
relevant to investigate if the candidate biomarkers can be detected in non-invasive patient samples, such as blood 
or expectorates, as this would allow them to be used in screening programs of high-risk individuals, such as 
patients suffering from chronic obstructive pulmonary disease (COPD) and thus enable early disease detection.
In conclusion, this study has identified 74 DMRs in LAC through a genome-wide methylation screening and 
confirmed significant changes in methylation for 15 selected regions in a LAC patient cohort using MS-HRM 
analysis. These 15 DMRs can be targeted as novel diagnostic biomarkers in LAC.
Methods
Patient samples. The regional ethical committee (De Videnskabsetiske Komitéer Region Midtjylland, 
Permission No.: 1-10-72-20-14) approved this study and all experiments were performed in accordance with the 
approved guidelines and regulations. Formalin-fixed, paraffin embedded (FFPE) blocks of surgical resections 
from lung adenocarcinoma (LAC) patients were selected from the archives at the Institute of Pathology, Aarhus 
University Hospital. Primary lung tumor and tumor-adjacent normal lung tissue from four LAC patients were 
used for the microarray analysis. For validation, 52 LAC patients were selected. These patients were divided 
into two cohorts matched on gender, age, smoking status, histology, T-stage and proportion of tumor cells. The 
first cohort comprises FFPE primary tumor and paired metastatic tissue (20 brain and 4 adrenal gland) from 
26 patients that suffered from distant metastatic disease at the time of diagnosis. The second cohort comprises 
FFPE primary tumor tissue from 26 distant metastases-free patients with a minimum of 5 years recurrence-free 
survival following surgical resection. The histological and clinical characteristics for the 52 patients are shown in 
Supplementary Table S317. FFPE tumor-adjacent normal lung tissue was selected by an experienced pathologist 
from 32 LAC patients and used as a control cohort. Peripheral blood samples obtained from healthy medical 
students of both sexes were used to generate unmethylated control DNA. Written informed consent was obtained 
from the subjects.
DNA extraction and Sodium Bisulfite treatment. For each FFPE sample, DNA was extracted from 
5 × 10 μ m sections using the QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden, Germany) according to the manu-
facturer’s protocol. DNA was extracted from the peripheral blood (PB) samples using a modified salt precipitation 
protocol. In brief, 10 ml blood was incubated for 30 min at 4 °C with 40 ml Triton lysis buffer (1% Triton X-100, 
10 mM Tris, 0.32 M sucrose, 5 mM MgCl2) and spun for 30 min at 3–4000 rpm (4 °C). The supernatant was then 
removed and the nuclei were washed using 0.9% NaCl. After a 10 min spin 2300 rpm, the remaining supernatant 
ID
Cutoff Value Normal Lung Lung Tumor
Sensitivity Specificity
Methylation 
Level
True Negative 
n (%)
False positive 
n (%) N (%)
False Negative 
n (%)
True Positive 
n (%) N (%)
OSR1 > 1% 30 (96.8) 1 (3.2) 31 (100) 1 (2.1) 47 (97.9) 48 (100) 0.98 0.97
SIM1 > 1% 28 (90.3) 3 (9.7) 31 (100) 4 (8.2) 45 (91.8) 49 (100) 0.92 0.90
HOXD10 > 1% 26 (81.3) 6 (18.7) 32 (100) 5 (9.8) 46 (90.2) 51 (100) 0.90 0.81
HIST1H3E > 50% 29 (90.6) 3 (9.4) 32 (100) 5 (10.0) 45 (90.0) 50 (100) 0.90 0.91
HOXD3 > 10% 30 (96.8) 1 (3.2) 31 (100) 7 (14.0) 43 (86.0) 50 (100) 0.86 0.97
GHSR > 10% 30 (96.8) 1 (3.2) 31 (100) 8 (16.7) 40 (83.3) 48 (100) 0.83 0.97
Chr1(q21.1).A > 10% 30 (100) 0 (0) 30 (100) 10 (20.8) 38 (79.2) 48 (100) 0.79 1.00
HOXB3/HOXB4 > 1% 31 (100) 0 (0) 31 (100) 12 (25.0) 36 (75.0) 48 (100) 0.75 1.00
Chr6(p22.1) > 1% 32 (100) 0 (0) 32 (100) 16 (32.6) 33 (67.4) 49 (100) 0.67 1.00
HIST1H3G/HIST1H2BI > 1% 32 (100) 0 (0) 32 (100) 19 (36.5) 33 (63.5) 52 (100) 0.63 1.00
OTX2 > 1% 31 (100) 0 (0) 31 (100) 25 (49.0) 26 (51.0) 51 (100) 0.51 1.00
LOC648987 > 1% 29 (100) 0 (0) 29 (100) 34 (75.5) 11 (24.5) 45 (100) 0.24 1.00
HIST1H2AJ/HIST1H2BM > 1% 32 (100) 0 (0) 32 (100) 40 (78.4) 11 (21.6) 51 (100) 0.22 1.00
HOXA3 > 50% 29 (100) 0 (0) 29 (100) 43 (86.0) 7 (14.0) 50 (100) 0.14 1.00
HOXA5 > 50% 31 (100) 0 (0) 31 (100) 46 (88.4) 6 (11.6) 52 (100) 0.12 1.00
Table 3.  Performance of MS-HRM assays.
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was discarded and the nuclei were lysed using 3 ml nuclei lysis buffer (24 mM EDTA, 75 mM NaCl), 230 μ l 10% 
SDS and 25 μ l pronase (20 mg/ml) and left shaking at room temperature over night. For each 3 ml nuclei lysis 
buffer, 1 ml saturated NaCl (6 M) was added and the mix was vigorously shaken for 15 sec. The supernatant was 
collected after a 15 min spin at 3000 rpm (4 °C) and transferred to a new tube. After an additional 15 min spin 
at 3000 rpm (4 °C), isopropanol was added (1:1) to the supernatant and gently shaken until the DNA precip-
itated. The precipitated DNA was then collected mechanically using a blunt end glass rod and transferred to 
a tube containing 400 μ l double-distilled H2O. DNA concentrations were measured using a NanoDrop 1000 
spectrophotometer (Thermo Scientific, Waltham, MA, USA). For MS-HRM analysis, 500 ng genomic DNA from 
each sample was subjected to sodium bisulfite treatment using the EZ-96 DNA Methylation-Gold™ kit (Zymo 
Research, Irvine, USA) according to the manufacturer´s instructions and eluted in a final volume of 52 μ l.
Microarray Analyses. The microarray based screening for differentially methylated regions (DMRs) was 
performed as previously described34. Briefly, DNA was extracted from primary tumor and tumor-adjacent nor-
mal lung tissue from four LAC patients. After DNA extraction, a methylated DNA immunoprecipitation (MeDIP) 
was performed in order to enrich the methylated fragments. A detailed description of the MeDIP protocol can be 
found in34. Two fractions from each sample (MeDIP enriched and input) were subsequently labeled with Cy5 and 
Cy3 and cohybridized to the NimbleGen Human DNA Methylation 3 × 720 K CpG Island Plus RefSeq Promoter 
Array (Roche/NimbleGen, Madison, WI, USA). The arrays were processed using NimbleScan software (Roche/
NimbleGen, Madison, WI, USA) to generate log2 signal ratios for each probe. The ratios were then averaged 
within each group (tumor and normal lung) and subsequently processed by the NimbleScan software to generate 
a relative enrichment score for each group. The enrichment scores for each group were then subtracted to produce 
a differential methylation score indicating an enrichment or depletion of signal in the tumor group relative to the 
normal lung group. Hence, negative and positive differential methylation scores indicate potentially hypo- and 
hypermethylated loci in lung cancer, respectively. A threshold of 2 was applied to the differential methylation 
score. A large fraction of the probes with differential methylation scores ≥ 2 were located in close proximity and 
the probes that were located within 5000 bp of each other were therefore grouped into differentially methylated 
regions (DMRs) with at least two probes targeting each DMR. Eighteen DMRs were then selected for validation 
based on the differential methylation score and the number of probes that mapped to the region. Previously 
undescribed and hypermethylated regions were prioritized. All validation experiments were performed using 
MS-HRM.
Methylation-Sensitive High-Resolution Melting (MS-HRM). Validation of the 18 potential DMRs 
was performed by MS-HRM analysis35,36. The LightCycler® 480 platform (Roche, Mannheim, Germany) was 
used for PCR and HRM, and each reaction comprised 1× MeltDoctorTM HRM Master Mix (Life Technologies, 
Carlsbad, CA, USA), 3 mM MgCl2, 500 nM of each primer and 10 ng of bisulfite modified DNA in a final volume 
of 10 μ l. All primers were designed to amplify both methylated and unmethylated DNA as described by Wojdacz 
et al.37. The methylation status of each DMR was determined by comparing the melting profiles of each sample 
with a standard dilution series of fully methylated DNA (Universal Methylated Human DNA Standard, Zymo 
Research, Irvine, CA USA) into unmethylated DNA, which was generated by subjecting DNA extracted from PB 
to whole genome amplification (WGA) using the Illustra GenomiPhi V2 DNA Amplification Kit (GE Healthcare 
Life Sciences, Piscataway, NJ, USA) according to the manufacturer’s instructions. All analyses were performed in 
duplicates. The technical specifications for each of the 18 assays, including the genomic location of the used prim-
ers, PCR cycling and HRM protocol, as well as melting profiles of the standards are included as Supplementary 
Information.
Statistical analyses and calculation of sensitivity and specificity. Statistical analyses were done 
using GraphPad Prism version 6 software (GraphPad Software, La Jolla, CA, USA). A Mann-Whitney Test 
of Ranks was used to assess the statistical significance for each DMR. To perform this test, all samples were 
ranked based on the determined level of methylation for each DMR; 0–1% methylation was ranked 1, 1–10% 
methylation was ranked 2, 10–50% methylation was ranked 3 and 50–100% methylation was ranked 4. 
Two-tailed p-values ≤ 0.05 were considered statistically significant. To evaluate the clinical potential of the can-
didate biomarkers, we calculated the sensitivity and specificity for each region. The sensitivity was calculated 
as True Positives/(True Positives + False Negatives) and the specificity was calculated as True Negatives/(True 
Negatives + False Positives).
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